(Q22252712)

Dimensions Publication ID

Dimensions

6 February 2023

Joel Oger

2

Joel

Oger

1 reference

Dimensions Publication ID

Dimensions

1043444963

Clinical features of liver disturbance in rheumatoid diseases: clinicopathological study with special reference to the cause of liver disturbance

6 February 2023

language of work or name

English

0 references

publication date

November 2004

0 references

published in

Journal of Neurology

0 references

volume

251

0 references

issue

11

0 references

page(s)

1297-1303

0 references

cites work

1 reference

12 December 2020

Pemoline-induced autoimmune hepatitis

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Chemotherapeutic agents and hepatotoxicity

1 reference

12 December 2020

Prescribing for multiple sclerosis patients in general practice: a case-control study

1 reference

12 December 2020

The effect of interferon on the metabolism of LDLs

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Canadian Association of Gastroenterology Practice Guidelines: evaluation of abnormal liver enzyme tests

1 reference

12 December 2020

Alanine aminotransferase levels: what's normal?

1 reference

12 December 2020

Fulminant liver failure during interferon beta treatment of multiple sclerosis

1 reference

12 December 2020

Idiosyncratic acute hepatitis caused by paracetamol in two patients with melanoma treated with high-dose interferon-alpha

1 reference

12 December 2020

Abnormalities of Liver Function Tests In Thyrotoxicosis

1 reference

12 December 2020

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis

1 reference

12 December 2020

Plasma lipoprotein changes in humans induced by beta-interferon

1 reference

12 December 2020

Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis

1 reference

12 December 2020

A patient with primary biliary cirrhosis and multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Concurrence of multiple sclerosis and inflammatory bowel disease

1 reference

12 December 2020

Prospective study on the relationship between infections and multiple sclerosis exacerbations.

1 reference

12 December 2020

[Possibly ranitidine-induced autoimmune hepatitis]

1 reference

12 December 2020

Alteration of drug biotransformation and elimination during infection and inflammation

1 reference

12 December 2020

Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes

1 reference

12 December 2020

Treatment of spasticity with tizanidine in multiple sclerosis

1 reference

12 December 2020

Drug-induced liver diseases

1 reference

12 December 2020

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance

1 reference

12 December 2020

Changes in plasma enzyme activity after intramuscular injection of bupivacaine into the human biceps brachii.

1 reference

12 December 2020

Serum transaminase elevations as indicators of hepatic injury following the administration of drugs

1 reference

12 December 2020

Evaluation of abnormal liver-enzyme results in asymptomatic patients

1 reference

12 December 2020

Liver function and other blood chemistry tests in multiple sclerosis

1 reference

12 December 2020

Spontaneous reporting of adverse drug reactions. I: the data

1 reference

12 December 2020

Possible mechanisms of elevation of serum transaminase levels during interferon-beta therapy in chronic hepatitis C patients

1 reference

12 December 2020

Dantrolene sodium and hepatic injury

1 reference

12 December 2020

Herbal toxicity and fatal hepatic failure

1 reference

12 December 2020

Hepatotoxicity of paracetamol in combination with interferon and vinblastine

1 reference

12 December 2020

Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS.

1 reference

12 December 2020

Interferon treatment for multiple sclerosis: autoimmune complications may be lethal

1 reference

12 December 2020

Nitrofurantoin-induced immune-mediated lung and liver disease

1 reference

12 December 2020

Jaundice from potassium p-aminobenzoate

1 reference

12 December 2020

Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission

1 reference

12 December 2020

Criteria of drug-induced liver disorders. Report of an international consensus meeting

1 reference

12 December 2020

Drug-induced hepatotoxicity.

1 reference

12 December 2020

Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis

1 reference

12 December 2020

Interferon beta1a therapy changes lipoprotein metabolism in patients with multiple sclerosis

1 reference

12 December 2020

Autoimmune hepatitis and interferon beta-1a for multiple sclerosis

1 reference

12 December 2020

Serum aminotransferase concentration as evidence of hepatocellular damage

1 reference

12 December 2020

Smoking and alanine aminotransferase levels in hepatitis C virus infection: implications for prevention of hepatitis C virus progression

1 reference

12 December 2020

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

12 December 2020

Liver injury associated with the beta-interferons for MS: a comparison between the three products.

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-004-0619-5

7 January 2021